Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3, Open Label, Multi-centre, Randomised Controlled International Study in Ewing Sarcoma

Next Previous
Trial Profile

Phase 3, Open Label, Multi-centre, Randomised Controlled International Study in Ewing Sarcoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Busulfan (Primary) ; Fenretinide (Primary) ; Treosulfan (Primary) ; Zoledronic acid (Primary) ; Cyclophosphamide; Dactinomycin; Doxorubicin; Etoposide; Granulocyte colony-stimulating factors; Ifosfamide; Melphalan; Mesna; Vincristine
  • Indications Ewing's sarcoma
  • Focus Therapeutic Use
  • Acronyms EWING2008

Most Recent Events

  • 16 Oct 2023 Results published in the Clinical Cancer Research
  • 07 Jun 2022 Results of subgroup analysis assessing impact of adjuvant radiotherapy in patients with localized Ewing sarcoma at the extremities from this trial presented at the 58th Annual Meeting of the American Society of Clinical Oncology
  • 15 Apr 2022 Results (n=109) assessing effect of treosulfan and melphalan high-dose chemotherapy (TreoMel-HDT) followed by reinfusion of autologous hematopoietic stem cells on event-free survival (EFS) and overall survival in high-risk Ewing sarcoma, published in the Journal of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top